Author:
Waeckerle-Men Ying,Uetz-von Allmen Edith,Fopp Markus,von Moos Roger,Böhme Christel,Schmid Hans-Peter,Ackermann Daniel,Cerny Thomas,Ludewig Burkhard,Groettrup Marcus,Gillessen Silke
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Reference40 articles.
1. Jones GW, Mettlin C, Murphy GP, Guinan P, Herr HW, Hussey DH, Chmiel JS, Fremgen AM, Clive RE, Zuber-Ocwieja KE (1995) Patterns of care for carcinoma of the prostate gland: results of a national survey of 1984 and 1990. J Am Coll Surg 180:545–554
2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512
3. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520
4. Markiewicz M, Kast WM (2003) Advances in immunotherapy for prostate cancer. Adv Cancer Res 87:159–194
5. Tjoa BA, Simmons SJ, Elgamal A, Rogers M, Ragde H, Kenny GM, Troychak MJ, Boynton AL, Murphy GP (1999) Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 40:125–129
Cited by
99 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献